• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性肾切除术后局部区域复发的危险因素。

Risk factors for locoregional relapse after radical nephrectomy.

作者信息

Jhavar Sameer, Swanson Gregory, Pruszynski Jessica

机构信息

Department of Radiation Oncology, Scott and White Medical Center, Temple, Texas, USA.

Department of Biostatistics, Scott and White Medical Center, Temple, Texas, USA.

出版信息

Asia Pac J Clin Oncol. 2018 Jun;14(3):192-197. doi: 10.1111/ajco.12684. Epub 2017 May 10.

DOI:10.1111/ajco.12684
PMID:28488392
Abstract

AIM

To identify risk factors for locoregional relapse after radical nephrectomy for renal cell carcinoma.

METHODS

We retrospectively reviewed the charts of 259 patients who underwent radical nephrectomy for sporadic clinically localized unilateral renal cell carcinoma between 1998 and 2012. Relapse patterns (locoregional and/or distant) were identified. Relapse-free survival was calculated using Kaplan-Meier method. Factors associated with decreased relapse-free survival were identified using univariate and multivariate Cox proportional hazards regression model analysis. Locoregional relapse estimates were calculated for individual factors and combination of factors.

RESULTS

At a median follow-up of 68 months (interquartile range: 75 months), 24% patients relapsed. Of these, 54% had locoregional relapse. High-grade, positive margin, large tumor size and stage III/IV were associated with worse relapse-free survival on multivariate analysis. Locoregional relapse occurred among patients with tumor size >7-</ = 10 cm (22%), >10 cm (35%), stage III/IV (31%), grade III/IV (26%), renal vein invasion (22%), perinephric fat invasion (30%), </ = 7 cm plus grade III/IV (15%), >7 cm plus grade I/II (21%), >7 cm plus grade III/IV (48%), stage III/IV plus grade I/II (24%) and stage III/IV plus grade III/IV (45%).

CONCLUSION

We were able to discern risk factors (individual or in combination) associated with increased risk of locoregional relapse after radical nephrectomy for renal cell carcinoma. This could help distinguish patients who may benefit from adjuvant locoregionally directed therapy.

摘要

目的

确定肾细胞癌根治性肾切除术后局部区域复发的危险因素。

方法

我们回顾性分析了1998年至2012年间259例行根治性肾切除术治疗散发性临床局限性单侧肾细胞癌患者的病历。确定复发模式(局部区域和/或远处)。采用Kaplan-Meier法计算无复发生存率。使用单因素和多因素Cox比例风险回归模型分析确定与无复发生存率降低相关的因素。计算个体因素及因素组合的局部区域复发估计值。

结果

中位随访68个月(四分位间距:75个月),24%的患者复发。其中,54%有局部区域复发。多因素分析显示,高级别、切缘阳性、肿瘤体积大及Ⅲ/Ⅳ期与无复发生存率较差相关。肿瘤大小>7-≤10 cm(22%)、>10 cm(35%)、Ⅲ/Ⅳ期(31%)、Ⅲ/Ⅳ级(26%)、肾静脉侵犯(22%)、肾周脂肪侵犯(30%)、≤7 cm加Ⅲ/Ⅳ级(15%)、>7 cm加Ⅰ/Ⅱ级(21%)、>7 cm加Ⅲ/Ⅳ级(48%)、Ⅲ/Ⅳ期加Ⅰ/Ⅱ级(24%)和Ⅲ/Ⅳ期加Ⅲ/Ⅳ级(45%)的患者发生局部区域复发。

结论

我们能够识别出肾细胞癌根治性肾切除术后与局部区域复发风险增加相关的危险因素(单独或联合)。这有助于区分可能从辅助性局部区域定向治疗中获益的患者。

相似文献

1
Risk factors for locoregional relapse after radical nephrectomy.根治性肾切除术后局部区域复发的危险因素。
Asia Pac J Clin Oncol. 2018 Jun;14(3):192-197. doi: 10.1111/ajco.12684. Epub 2017 May 10.
2
Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.部分肾切除术与根治性肾切除术相比,与临床 T1 期肾细胞癌病理升级为 T3a 的患者复发风险更高。
J Urol. 2017 Aug;198(2):289-296. doi: 10.1016/j.juro.2017.03.012. Epub 2017 Mar 6.
3
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.部分和根治性肾切除术治疗良性肾肿瘤患者的 IV 期慢性肾脏病的总生存和发展。
Eur Urol. 2013 Oct;64(4):600-6. doi: 10.1016/j.eururo.2012.12.023. Epub 2012 Dec 25.
4
Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors.高风险肾肿瘤行部分肾切除术时,阳性切缘增加肿瘤复发风险。
J Urol. 2016 Aug;196(2):327-34. doi: 10.1016/j.juro.2016.02.075. Epub 2016 Feb 19.
5
Patient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy.患者报告的体重减轻可预测肾切除术后肾细胞癌病例的复发率。
Asian Pac J Cancer Prev. 2018 Apr 25;19(4):891-895. doi: 10.22034/APJCP.2018.19.4.891.
6
Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.根治性肾切除术后的阳性切缘是局部复发和疾病特异性生存的独立预测因子。
World J Surg Oncol. 2017 Nov 2;15(1):193. doi: 10.1186/s12957-017-1257-6.
7
Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors. Shah PH, Moreira DM, Okhunov Z, Patel VR, Chopra S, Razmaria AA, Alom M, George AK, Yaskiv O, Schwartz MJ, Desai M, Vira MA, Richstone L, Landman J, Shalhav AL, Gill I, Kavoussi LR. J Urol. 2016 Aug;196(2):327-34.阳性手术切缘增加高危肾肿瘤部分肾切除术后复发风险。沙阿·P·H、莫雷拉·D·M、奥胡诺夫·Z、帕特尔·V·R、乔普拉·S、拉兹马里亚·A·A、阿洛姆·M、乔治·A·K、亚斯基夫·O、施瓦茨·M·J、德赛·M、维拉·M·A、里奇斯通·L、兰德曼·J、沙尔哈夫·A·L、吉尔·I、卡武西·L·R。《泌尿外科杂志》。2016年8月;196(2):327 - 34。
Urol Oncol. 2017 Jun;35(6):449-450. doi: 10.1016/j.urolonc.2017.03.013. Epub 2017 Apr 14.
8
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.接受保留肾单位手术或根治性手术治疗的低分期肾细胞癌患者的疾病转归。
J Urol. 1996 Jun;155(6):1868-73.
9
Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.肾周脂肪浸润和肿瘤大小在肾细胞癌中的预后意义
J Urol. 2008 Aug;180(2):486-91; discussion 491. doi: 10.1016/j.juro.2008.04.034. Epub 2008 Jun 11.
10
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).肾细胞癌肾切除术后 5 年以上复发相关特征:基于大型多中心数据库(CORONA/SATURN 项目)开发和内部验证预测晚期复发的风险模型(PRELANE 评分)。
Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22.

引用本文的文献

1
Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma.局部进展期肾细胞癌根治性肾切除术后局部区域复发的危险因素和模式。
Cancer Res Treat. 2022 Jan;54(1):218-225. doi: 10.4143/crt.2020.1373. Epub 2021 Apr 15.
2
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.索拉非尼作为转移性肾细胞癌二线治疗在墨西哥的应用:一项前瞻性队列研究。
BMC Cancer. 2021 Jan 5;21(1):16. doi: 10.1186/s12885-020-07720-5.